SignalGene Announces Appointment of George W. Masters to Board of Directors.Health/Medical Writers MONTREAL--(BW HealthWire)--Sept. 28, 2000 Dr. Michael Dennis, Chairman of the Board of SignalGene Inc.(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :SGI (SGI, Sunnyvale, CA, www.sgi.com) A manufacturer of workstations and servers, founded in 1982 by Jim Clark. The company was founded as Silicon Graphics, Inc., but changed to its acronym in 1999. .), is pleased to announce the appointment of Mr. George W. Masters to the Company's Board of Directors. This nomination is subject to approval by regulatory authorities. Mr. Masters has had an outstanding career as corporate executive and brings to SignalGene over thirty years of experience in the international healthcare and biotechnology industry. He spent almost twenty years TWENTY YEARS. The lapse of twenty years raises a presumption of certain facts, and after such a time, the party against whom the presumption has been raised, will be required to prove a negative to establish his rights. 2. with Warner-Lambert, a global healthcare company, his most senior position being Group President of the worldwide diagnostics business. Following that, Mr. Masters held the position of President and Chief Executive Officer of several North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. biopharmaceutical companies, including Immunomedics Inc., Verax Corporation, Seragen Inc. and Hemosol Inc., for which he has also served as Vice Chairman of the Board since 1992. Mr. Masters is currently non-executive Chairman of Guard Inc. and of Biocatalyst bi·o·cat·a·lyst n. A substance, especially an enzyme, that initiates or modifies the rate of a chemical reaction in a living body; a biochemical catalyst. bi Yorkton Inc., a Canadian venture capital firm. He also serves on the Board of Directors of numerous private biotechnology and healthcare companies and he is a past member of the Board of the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
"We are very pleased to have Mr. George Masters join SignalGene's Board of Directors," said Dr. Michael Dennis. "His broad experience as a Corporate Executive and Director in the biotechnology industry, along with his extensive network of industry contacts, will be of great assistance in defining and executing SignalGene's business strategy," added Dr. Dennis. Mr. Masters replaces Mr. Henri Harland, who is leaving his seat on SignalGene's Board of Directors. Mr. Harland was cofounder co·found tr.v. co·found·ed, co·found·ing, co·founds To establish or found in concert with another or others. co·found of the Company and has served on the Board of Directors since 1992. From May 1996 to December 1997, he was also Vice President, Corporate Development and CFO See Chief Financial Officer. of the Company. "We are very grateful to Mr. Harland for his valuable contribution to the Company over the years. His extensive expertise in private and public financing, strategic planning and corporate alliances have greatly benefited SignalGene," said Dr. Dennis. "It is with regret that we see him go and we wish him the best of luck in his future endeavours," concluded Dr. Dennis. SignalGene is an integrated genomics-based drug discovery company. By combining cutting-edge technologies in pharmacogenomics, functional genomics and drug design with world-class scientific collaborations with university and hospital researchers, SignalGene is taking a leading role in the conversion of genomic information into novel diagnostic and therapeutic products for major human diseases. Current research programs target metabolic disorders (obesity), women's health (breast cancer and osteoporosis), inflammatory disorders (psoriasis) and neurodegenerative disorders (Alzheimer's disease). The Company generates short-term revenues, through its GLP-based pharmacogenomics services and technology-based discovery collaborations, while pursuing its internal research and development programs for partnering with major pharmaceutical companies. The shares of the Company are listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol SGI. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion